細胞・遺伝子治療薬送達デバイス市場-世界産業規模、シェア、動向、機会、予測、2018-2028年タイプ別(網膜下注入カニューレ、延長チューブ、静脈内カテーテル、滅菌インスリンシリンジ、プレフィルドシリンジ、輸液バッグ)、市販薬別(Luxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelis)、投与経路別(経口、静脈内、眼、経皮、その他)、方法別(In Vitro v/s Ex Vivo)、地域別および競合別Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028Segmented By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags), By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis), By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others), By Method (In Vitro v/s Ex Vivo), By Region and Competition 細胞・遺伝子治療薬送達デバイスの世界市場は、予測期間2024-2028年に力強い成長を示すと予想される。この背景には、癌などの様々な慢性疾患の治療における細胞・遺伝子治療の利用が拡大していることがある。細胞... もっと見る
サマリー細胞・遺伝子治療薬送達デバイスの世界市場は、予測期間2024-2028年に力強い成長を示すと予想される。この背景には、癌などの様々な慢性疾患の治療における細胞・遺伝子治療の利用が拡大していることがある。細胞・遺伝子治療中の薬物投与量を効率的にモニタリングできるドラッグデリバリーデバイスに対する需要の高まりが、今後数年間の市場成長を支えるものと予想される。細胞・遺伝子治療は、効率的な可能性を秘めた革新的な産業である。細胞・遺伝子治療には、ドナーから細胞、タンパク質、遺伝物質(DNA)を抽出し、それらを改変して高度に特異的で個別化された治療を提供することが含まれる。個別化医療の人気の高まりは、細胞・遺伝子治療の需要を大幅に増加させ、その結果、これらの治療を提供するために使用される装置の需要を生み出している。 効果的な投与は、標的部位における薬剤の生物学的利用能を最大化するのに役立ち、患者にとって便利であるため、今後数年間、細胞療法や遺伝子療法を含むさまざまな治療法の送達に使用される機器の成長を積極的に支援する。リングやパッチなどのバリエーションとして市場で入手可能な皮下インプラントのような新しい薬物送達システムは、予測期間における世界の細胞・遺伝子治療薬物送達デバイス市場の成長を後押しすると予想される。 慢性疾患の有病率の増加 人口の間で癌の有病率が憂慮すべき割合で増加しており、効果的な治療法の必要性が様々な細胞・遺伝子療法の開発につながった。細胞療法と遺伝子療法の開発は、それらを提供するために使用されるさまざまなデバイスの需要の増加につながり、それによって世界の細胞療法と遺伝子療法薬物送達デバイスの成長を推進している。Globocan 2020によると、世界中で新たに報告された癌の症例は約19,292,789件である。そのうち10,065,305人が男性で、肺がん、前立腺がん、大腸がん、胃がん、肝臓がんで占められている。同様に、女性で報告された新規がん症例数は約9,227,484例で、乳がん、大腸がん、肺がん、子宮頸がん、甲状腺がんが最も多い。 細胞・遺伝子治療と臨床試験に関するFDA承認の増加 2017年に最初の治療法が承認され、細胞療法と遺伝子療法は投資の世界では比較的新しいものである。Cell and Gene Journalによると、FDAが承認した22の細胞療法と遺伝子療法のうち、14は臍帯血ベースの治療法である。残りの承認は、2つの遺伝子療法、7つの細胞療法、5つの改変細胞療法である。また、承認された340の生物製剤のうち、細胞・遺伝子治療は全体のわずか7%である。また、2021年にFDAが承認した50以上の医薬品のうち、細胞・遺伝子治療はわずか2つである。2021年に承認された医薬品全体に占める割合は少ないが、承認された細胞・遺伝子治療薬が10%増加したことを反映しており、医学の発展における目覚ましい一歩である。このように、より優れたドラッグデリバリーデバイスを提供する最新の発売に対するFDAの承認数の増加は、細胞および遺伝子療法を提供するために使用されるデバイスの開発のための様々な企業の間で人気を集めている。このことは、今後数年間、世界の細胞・遺伝子治療薬物送達装置市場の成長を後押しすると予想される。 細胞・遺伝子治療市場への投資と資金調達の増加 細胞治療・遺伝子治療企業は、民間および公的投資による優れた金額と比率を得ている。治療法が確立されていない疾患や慢性疾患をターゲットとする新規細胞・遺伝子治療の保証は、民間投資、新規株式公開、企業からの多額の資金流入につながっている。ライフ・サイエンスへの民間投資の増加に伴い、細胞治療と遺伝子治療への投資も急増している。Cell and Gene Journal誌によると、2010年から2021年にかけての投資成長率は、遺伝子治療が59%であるのに対し、細胞治療は63%であり、これはより高い成長率であると同時に、予測期間中に世界の細胞・遺伝子治療薬物送達デバイス市場の成長を後押しする重要な役割をもたらすと予想されている。 また、いくつかの国の様々な政府は、患者や医師の間でデバイスに関する認識を高めるプロセスを支援しており、それによって細胞&遺伝子治療薬物送達デバイスの世界市場の成長をサポートしています。 市場セグメンテーション 細胞・遺伝子治療薬物送達デバイスの世界市場は、タイプ、製品化された薬剤、投与経路、方法、地域によって細分化される。タイプ別では、網膜下注入カニューレ、延長チューブ、静脈内カテーテル、滅菌インスリン注射器、プレフィルドシリンジ、輸液バッグに細分化される。商品化された薬剤に基づき、市場はさらにLuxturna、Kymriah、Yescarta、Zolgensma、Provenge、Strimvelisに細分化される。投与経路によって、市場はさらに経口、静脈内、眼、経皮、その他に区分される。投与方法の種類によって、市場は体外と生体外に区分される。地域別では、北米、欧州、アジア太平洋、南米、中東・アフリカに分布する。 市場プレイヤー Becton, Dickinson, and Company、Novartis AG、Amgen Inc.、Kite Pharma, Inc.、Pfizer, Inc.、Bausch & Lomb Incorporated、Bluebird bio, Inc.、Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.)、Dendreon Pharmaceuticals LLC.、Helixmith Co、Ltd.(ViroMed社)、Orchard Therapeutics plc、Renova Therapeutics、Spark Therapeutics, Inc.、uniQure N.V.、Vericel Corporationなどが、世界の細胞・遺伝子治療薬物送達装置市場で事業を展開する大手企業である。 レポートの範囲 本レポートでは、細胞・遺伝子治療薬物送達デバイスの世界市場を、業界動向に加えて、以下のカテゴリーに分類しています: - 細胞・遺伝子治療薬物送達デバイス市場、タイプ別 o 網膜下注入カニューレ o 延長チューブ o 静脈カテーテル o 滅菌インスリンシリンジ o プレフィルドシリンジ o 輸液バッグ - 細胞・遺伝子治療薬送達デバイス市場、市販薬別 o ラクストゥーナ o キムリア o イエスカルタ o ゾルゲンマ o プロベンジ o ストリムベリス - 細胞・遺伝子治療薬物送達デバイス市場、投与経路別 o 経口 o 静注 o 眼 o 経皮 o その他 - 細胞・遺伝子治療薬物送達デバイス市場、方法別 o 体外 生体外 - 細胞・遺伝子治療薬物送達デバイス市場:地域別 北米 米国 カナダ メキシコ 欧州 ドイツ フランス イギリス イタリア スペイン o アジア太平洋 中国 日本 インド 韓国 オーストラリア 中東・アフリカ 南アフリカ サウジアラビア アラブ首長国連邦 o 南米 ブラジル アルゼンチン コロンビア 競争状況 企業プロフィール:世界の細胞・遺伝子治療薬送達デバイス市場に参入している主要企業の詳細分析。 利用可能なカスタマイズ: TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です: 企業情報 - 追加市場参入企業(最大5社)の詳細分析とプロファイリング 目次1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Clinical Trial Analysis 5.1. Ongoing Clinical Trials 5.2. Completed Clinical Trials 5.3. Terminated Clinical Trials 5.4. Breakdown of Pipeline, By Development Phase 5.5. Breakdown of Pipeline, By Status 5.6. Breakdown of Pipeline, By Study Type 5.7. Breakdown of Pipeline, By Region 5.8. Clinical Trials Heat Map 6. Global Cell & Gene Therapy Drug Delivery Devices Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 6.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 6.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 6.2.4. By Method (In Vitro v/s Ex Vivo) 6.2.5. By Company (2022) 6.2.6. By Region 6.3. Market Map 6.3.1. By Type 6.3.2. By Commercialized Drugs 6.3.3. By Route of Administration 6.3.4. By Method 6.3.5. By Region 7. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 7.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 7.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 7.2.4. By Method (In Vitro v/s Ex Vivo) 7.2.5. By Country 7.3. Asia-Pacific: Country Analysis 7.3.1. China Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Type 7.3.1.2.2. By Commercialized Drugs 7.3.1.2.3. By Route of Administration 7.3.1.2.4. By Method 7.3.2. India Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Type 7.3.2.2.2. By Commercialized Drugs 7.3.2.2.3. By Route of Administration 7.3.2.2.4. By Method 7.3.3. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Type 7.3.3.2.2. By Commercialized Drugs 7.3.3.2.3. By Route of Administration 7.3.3.2.4. By Method 7.3.4. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Type 7.3.4.2.2. By Commercialized Drugs 7.3.4.2.3. By Route of Administration 7.3.4.2.4. By Method 7.3.5. Australia Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Type 7.3.5.2.2. By Commercialized Drugs 7.3.5.2.3. By Route of Administration 7.3.5.2.4. By Method 8. Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 8.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 8.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 8.2.4. By Method (In Vitro v/s Ex Vivo) 8.2.5. By Country 8.3. Europe: Country Analysis 8.3.1. France Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Type 8.3.1.2.2. By Commercialized Drugs 8.3.1.2.3. By Route of Administration 8.3.1.2.4. By Method 8.3.2. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Type 8.3.2.2.2. By Commercialized Drugs 8.3.2.2.3. By Route of Administration 8.3.2.2.4. By Method 8.3.3. United Kingdom Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Type 8.3.3.2.2. By Commercialized Drugs 8.3.3.2.3. By Route of Administration 8.3.3.2.4. By Method 8.3.4. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Type 8.3.4.2.2. By Commercialized Drugs 8.3.4.2.3. By Route of Administration 8.3.4.2.4. By Method 8.3.5. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Type 8.3.5.2.2. By Commercialized Drugs 8.3.5.2.3. By Route of Administration 8.3.5.2.4. By Method 9. North America Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 9.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 9.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 9.2.4. By Method (In Vitro v/s Ex Vivo) 9.2.5. By Country 9.3. North America: Country Analysis 9.3.1. United States Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Type 9.3.1.2.2. By Commercialized Drugs 9.3.1.2.3. By Route of Administration 9.3.1.2.4. By Method 9.3.2. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Type 9.3.2.2.2. By Commercialized Drugs 9.3.2.2.3. By Route of Administration 9.3.2.2.4. By Method 9.3.3. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Type 9.3.3.2.2. By Commercialized Drugs 9.3.3.2.3. By Route of Administration 9.3.3.2.4. By Method 10. South America Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 10.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 10.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 10.2.4. By Method (In Vitro v/s Ex Vivo) 10.2.5. By Country 10.3. South America: Country Analysis 10.3.1. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Type 10.3.1.2.2. By Commercialized Drugs 10.3.1.2.3. By Route of Administration 10.3.1.2.4. By Method 10.3.2. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Type 10.3.2.2.2. By Commercialized Drugs 10.3.2.2.3. By Route of Administration 10.3.2.2.4. By Method 10.3.3. Colombia Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Type 10.3.3.2.2. By Commercialized Drugs 10.3.3.2.3. By Route of Administration 10.3.3.2.4. By Method 11. Middle East and Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 11.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 11.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 11.2.4. By Method (In Vitro v/s Ex Vivo) 11.2.5. By Country 11.3. MEA: Country Analysis 11.3.1. South Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.3.1.1. Market Size & Forecast 11.3.1.1.1. By Value 11.3.1.2. Market Share & Forecast 11.3.1.2.1. By Type 11.3.1.2.2. By Commercialized Drugs 11.3.1.2.3. By Route of Administration 11.3.1.2.4. By Method 11.3.2. Saudi Arabia Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.3.2.1. Market Size & Forecast 11.3.2.1.1. By Value 11.3.2.2. Market Share & Forecast 11.3.2.2.1. By Type 11.3.2.2.2. By Commercialized Drugs 11.3.2.2.3. By Route of Administration 11.3.2.2.4. By Method 11.3.3. UAE Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.3.3.1. Market Size & Forecast 11.3.3.1.1. By Value 11.3.3.2. Market Share & Forecast 11.3.3.2.1. By Type 11.3.3.2.2. By Commercialized Drugs 11.3.3.2.3. By Route of Administration 11.3.3.2.4. By Method 12. Market Dynamics 12.1. Drivers 12.2. Challenges 13. Market Trends & Developments 13.1. Recent Developments 13.2. Mergers & Acquisitions 13.3. Product Launches 14. Competitive Landscape 14.1. Business Overview 14.2. Company Snapshot 14.3. Products & Services 14.4. Financials (As Reported) 14.5. Recent Developments 14.6. SWOT Analysis 14.6.1. Becton, Dickinson, and Company 14.6.2. Novartis AG 14.6.3. Amgen Inc. 14.6.4. Kite Pharma, Inc. 14.6.5. Pfizer, Inc. 14.6.6. Bausch & Lomb Incorporated 14.6.7. Bluebird bio, Inc. 14.6.8. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.) 14.6.9. Dendreon Pharmaceuticals LLC. 14.6.10. Helixmith Co., Ltd (ViroMed Co., Ltd) 15. Strategic Recommendations
SummaryGlobal Cell & Gene Therapy Drug Delivery Devices market is expected to show robust growth in the forecast period, 2024-2028. This can be attributed to the growing use of cell and gene therapy for the treatment of various chronic diseases such as cancer. The increasing demand for drug delivery devices that are efficient in monitoring drug dosage during cell and gene therapies is expected to support market growth in the coming years. Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Clinical Trial Analysis 5.1. Ongoing Clinical Trials 5.2. Completed Clinical Trials 5.3. Terminated Clinical Trials 5.4. Breakdown of Pipeline, By Development Phase 5.5. Breakdown of Pipeline, By Status 5.6. Breakdown of Pipeline, By Study Type 5.7. Breakdown of Pipeline, By Region 5.8. Clinical Trials Heat Map 6. Global Cell & Gene Therapy Drug Delivery Devices Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 6.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 6.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 6.2.4. By Method (In Vitro v/s Ex Vivo) 6.2.5. By Company (2022) 6.2.6. By Region 6.3. Market Map 6.3.1. By Type 6.3.2. By Commercialized Drugs 6.3.3. By Route of Administration 6.3.4. By Method 6.3.5. By Region 7. Asia-Pacific Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 7.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 7.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 7.2.4. By Method (In Vitro v/s Ex Vivo) 7.2.5. By Country 7.3. Asia-Pacific: Country Analysis 7.3.1. China Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Type 7.3.1.2.2. By Commercialized Drugs 7.3.1.2.3. By Route of Administration 7.3.1.2.4. By Method 7.3.2. India Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Type 7.3.2.2.2. By Commercialized Drugs 7.3.2.2.3. By Route of Administration 7.3.2.2.4. By Method 7.3.3. South Korea Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Type 7.3.3.2.2. By Commercialized Drugs 7.3.3.2.3. By Route of Administration 7.3.3.2.4. By Method 7.3.4. Japan Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Type 7.3.4.2.2. By Commercialized Drugs 7.3.4.2.3. By Route of Administration 7.3.4.2.4. By Method 7.3.5. Australia Cell & Gene Therapy Drug Delivery Devices Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Type 7.3.5.2.2. By Commercialized Drugs 7.3.5.2.3. By Route of Administration 7.3.5.2.4. By Method 8. Europe Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 8.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 8.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 8.2.4. By Method (In Vitro v/s Ex Vivo) 8.2.5. By Country 8.3. Europe: Country Analysis 8.3.1. France Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Type 8.3.1.2.2. By Commercialized Drugs 8.3.1.2.3. By Route of Administration 8.3.1.2.4. By Method 8.3.2. Germany Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Type 8.3.2.2.2. By Commercialized Drugs 8.3.2.2.3. By Route of Administration 8.3.2.2.4. By Method 8.3.3. United Kingdom Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Type 8.3.3.2.2. By Commercialized Drugs 8.3.3.2.3. By Route of Administration 8.3.3.2.4. By Method 8.3.4. Italy Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Type 8.3.4.2.2. By Commercialized Drugs 8.3.4.2.3. By Route of Administration 8.3.4.2.4. By Method 8.3.5. Spain Cell & Gene Therapy Drug Delivery Devices Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Type 8.3.5.2.2. By Commercialized Drugs 8.3.5.2.3. By Route of Administration 8.3.5.2.4. By Method 9. North America Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 9.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 9.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 9.2.4. By Method (In Vitro v/s Ex Vivo) 9.2.5. By Country 9.3. North America: Country Analysis 9.3.1. United States Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Type 9.3.1.2.2. By Commercialized Drugs 9.3.1.2.3. By Route of Administration 9.3.1.2.4. By Method 9.3.2. Mexico Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Type 9.3.2.2.2. By Commercialized Drugs 9.3.2.2.3. By Route of Administration 9.3.2.2.4. By Method 9.3.3. Canada Cell & Gene Therapy Drug Delivery Devices Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Type 9.3.3.2.2. By Commercialized Drugs 9.3.3.2.3. By Route of Administration 9.3.3.2.4. By Method 10. South America Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 10.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 10.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 10.2.4. By Method (In Vitro v/s Ex Vivo) 10.2.5. By Country 10.3. South America: Country Analysis 10.3.1. Brazil Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Type 10.3.1.2.2. By Commercialized Drugs 10.3.1.2.3. By Route of Administration 10.3.1.2.4. By Method 10.3.2. Argentina Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Type 10.3.2.2.2. By Commercialized Drugs 10.3.2.2.3. By Route of Administration 10.3.2.2.4. By Method 10.3.3. Colombia Cell & Gene Therapy Drug Delivery Devices Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Type 10.3.3.2.2. By Commercialized Drugs 10.3.3.2.3. By Route of Administration 10.3.3.2.4. By Method 11. Middle East and Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) 11.2.2. By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) 11.2.3. By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) 11.2.4. By Method (In Vitro v/s Ex Vivo) 11.2.5. By Country 11.3. MEA: Country Analysis 11.3.1. South Africa Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.3.1.1. Market Size & Forecast 11.3.1.1.1. By Value 11.3.1.2. Market Share & Forecast 11.3.1.2.1. By Type 11.3.1.2.2. By Commercialized Drugs 11.3.1.2.3. By Route of Administration 11.3.1.2.4. By Method 11.3.2. Saudi Arabia Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.3.2.1. Market Size & Forecast 11.3.2.1.1. By Value 11.3.2.2. Market Share & Forecast 11.3.2.2.1. By Type 11.3.2.2.2. By Commercialized Drugs 11.3.2.2.3. By Route of Administration 11.3.2.2.4. By Method 11.3.3. UAE Cell & Gene Therapy Drug Delivery Devices Market Outlook 11.3.3.1. Market Size & Forecast 11.3.3.1.1. By Value 11.3.3.2. Market Share & Forecast 11.3.3.2.1. By Type 11.3.3.2.2. By Commercialized Drugs 11.3.3.2.3. By Route of Administration 11.3.3.2.4. By Method 12. Market Dynamics 12.1. Drivers 12.2. Challenges 13. Market Trends & Developments 13.1. Recent Developments 13.2. Mergers & Acquisitions 13.3. Product Launches 14. Competitive Landscape 14.1. Business Overview 14.2. Company Snapshot 14.3. Products & Services 14.4. Financials (As Reported) 14.5. Recent Developments 14.6. SWOT Analysis 14.6.1. Becton, Dickinson, and Company 14.6.2. Novartis AG 14.6.3. Amgen Inc. 14.6.4. Kite Pharma, Inc. 14.6.5. Pfizer, Inc. 14.6.6. Bausch & Lomb Incorporated 14.6.7. Bluebird bio, Inc. 14.6.8. Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.) 14.6.9. Dendreon Pharmaceuticals LLC. 14.6.10. Helixmith Co., Ltd (ViroMed Co., Ltd) 15. Strategic Recommendations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社の世界/地域別市場調査分野での最新刊レポート
本レポートと同じKEY WORD(devices)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/14 10:27 156.77 円 166.04 円 201.95 円 |